

Pharmacogenomics

Session 1 OPENING SESSION

WEDNESDAY 11/19/2008, 7:30 PM

R.M. Weinshilbourn / J.S. Leeder

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
1	Berg	Mechanisms of the path to personalized medicine	25
	Spielberg	No title	25
2	Weiss	Asthma pharmacogenetics—Genome wide association analysis for inhaled steroid treatment response	25

Session 2 WHOLE-GENOME ASSOCIATIONS AND TRANSLATIONAL

THURSDAY 11/20/2008, 9:00 AM

M. Eichelbaum / C.R. Wolf

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
	Deloukas	No title	25
3	Butte	Exploring genomic medicine and pharmacogenomics using translational bioinformatics	25
4	Dickson	Influence of the globalization of clinical trials on genetic study design and analysis	25
5	Rodin	Multi-step GWA data analysis strategy—Data mining methodology for Pharmacogenetics association studies	25
6	van den Oord	A genome-wide association study of response to treatment with antipsychotics	25
7	Hansen	Informing pharmacogenomics studies with prior scientific knowledge	25

Session 3 POSTER SESSION I

THURSDAY 11/20/2008, 2:00 PM

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
8	Adams	Development of a 5-lipoxygenase pathway-focused pharmacogenomics panel for use in the treatment of atherosclerosis and asthma	
9	Aleksunes	Nrf2 deletion impairs glucose tolerance and exacerbates hyperglycemia in the type 1 diabetic mice	
10	Pirmohamed	Carbamazepine-induced hypersensitivity in Caucasians and genetic polymorphisms in the major histocompatibility complex	
11	Arafah	The pharmacogenetics of renal transporters (OAT1, OAT2 and OCT2) on triglyceride response to fenofibrate in vivo considering coadministered drugs	
12	Mehlotra	Population genetic structures of <i>CYP2B6</i> and <i>UGT2B7</i> —Implications for HIV/AIDS treatment	
14	Ross	Canadian Pharmacogenomics Network for Drug Safety (CPNDS)—A Canadian national active surveillance network for adverse drug reactions	
15	Pirmohamed	Genetic variation of the one carbon folate pathway—A bioinformatic analysis	
16	JEONG	Association between H111H polymorphism and gene expression of beta arrestin 1 gene (ARRB1) in Korean major depressive disorder	
17	Conti	A pay for performance model of pricing PGX-based diagnostic tests	

18	Fukushima	Reduced transport of tenofovir by MRP4 variants
19	Garten	Mining the pharmacogenomics literature to create interaction networks and promote discovery
20	Kennedy	In vitro expression analysis and association study provide evidence for adrenomedullin involvement in response to the antidepressant paroxetine
21	Gong	PharmGKB new initiatives—A nexus for pharmacogenomic research
22	Corey	CYP2D6 polymorphisms in Puerto Rican psychiatric patients with adverse events
24	Ramatoulie	Effects of genetic variation at the chromosome 10 CYP2C19/CYP2C9 locus on chlorcycloguanil pharmacokinetics in Gambians
25	JEONG	Positive association between -182T/C polymorphism and promoter activity of norepinephrine transporter gene (SLC6A2) in Korean major depressive disorder
26	JEONG	Association between Leptin gene -2548A/G polymorphisms and mirtazapine-induced weight gain
27	Kennedy	Analysis of multiple smoking behavior measures in a longitudinal study provides no support for a role of the <i>CHRNA3-CHRNA5</i> genomic region in nicotine addiction
28	Kim	Genetic variations associated with the dermatologic adverse drug reactions of antiepileptic agents
29	LaFond	Substrate-dependent effects of non-synonymous variants of <i>ABCG2</i>
30	Lee	Functional characterization of new <i>CYP2C19</i> variants and haplotype analysis of <i>CYP2C9</i> and <i>CYP2C19</i> in a Korean population
31	Lee	Genetic interaction between <i>CD40</i> and <i>CD40L</i> is associated with antibiotics-induced cutaneous adverse reactions
32	Lencz	Dopamine receptor Pharmacogenetics in schizophrenia
34	Lindqvist-Appell	Explaining TPMT genotype/phenotype discrepancy by identification of a novel sequence variant, TPMT*26

Session 4 BASIC GENOMICS—DNA SEQUENCING AND CNV

THURSDAY 11/20/2008, 7:30 PM

M. Pirmohamed / M. Eichelbaum

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
	Wilson	No title	25
35	Feuk	Functional characteristics of common copy number variation in the human genome	25
36	Black III	CYP2D6—Mechanisms of copy number variation and other recombinant events	25
37	Huang	Population specific <i>GSTM1</i> copy number variation	25
38	Lubomirov	ADME pathway pharmacogenetics of antiretroviral agents lopinavir and tenofovir	25
39	Phillips	Development of a consensus list of ADME genes and polymorphisms for use in pharmaceutical clinical trials—The ADME "core list"	25

Session 5 CARDIOVASCULAR PHARMACOGENOMICS

FRIDAY 11/21/2008, 9:00 AM

D. Roden / A. Shuldiner

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
----------	--------------	--------------	--------------------

40	Roden	Pharmacogenetic approaches to the study of abnormal cardiac rhythm	25
	Shuldiner	No title	25
41	Port	Adrenergic receptor polymorphisms and response to budindolol in heart failure	25
42	Palmer	Common non-synonymous substitutions in SLC01B1 predispose to statin intolerance in routinely-treated individuals with type 2 diabetes	25
43	Wadelius	Pharmacogenomic warfarin dose refinement	25

Session 6 POSTER SESSION II

FRIDAY 11/21/2008, 2:00 PM

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
45	Madadi	Codeine use during breastfeeding—A need for individualized medicine	
46	Melis	Prospective pharmacogenetic-based warfarin dosing in orthopedic patients	
47	Newman	UGT1A1 promoter genotypes do not predict hematological toxicity in patients treated with intermediate dose irinotecan	
48	Mishra	The contribution of genetic factors in warfarin dose requirements in an ethnically diverse population	
49	Mongrain	The individualized selection of therapy for patients requiring frequent transfusions	
50	Mummaneni	Pediatric systemic lupus erythematosus (SLE) gene expression signatures and pathways—A pilot meta-analysis study	
51	Nagele	Influence of methylenetetrahydrofolate reductase (<i>MTHFR</i>) gene polymorphisms on homocysteine concentrations after nitrous oxide anesthesia	
52	Park	Profiling of alternative splice variants of CYP2D6 in human livers	
53	Perera	SNP picking, to resequence or to download—An evaluation of SNP chip technology and HapMap in the genotyping of pharmacogenomic genes	
54	Ramamoorthy	Identification of microRNAs that target HNF4A	
55	Riancho	Pharmacogenomics of osteoporosis—A pilot study on the response to antiresorptive agents	
56	Sagreiya	The pharmacogenomics of warfarin dosing	
57	Sangkuhl	PharmGKB—New features to broaden knowledge presentation	
58	Schroth	The coactivator PPARGC1B variant A203P promotes distant recurrences in breast cancer tamoxifen therapy	
59	Shah	Evaluation of <i>TGFB1</i> promoter and signal peptide polymorphisms as risk factors for renal dysfunction in hematopoietic transplant patients treated with cyclosporine A	
60	Shin	Genetic and functional variation of <i>CNT1</i> in a Korean population	
61	Skoglund	Low expression of TPMT wild type alleles in a patient with absent TPMT activity	
62	van Schaik	The <i>CYP2C19*17</i> allele is correlated with lower imipramine steady state plasma concentrations in depressed patients	
63	White	Development of a TaqMan® cytochrome p450 panel array and positive controls	

64	Windsor	A pilot pharmacogenomic study of the influence of cytotoxic target and metabolizing gene polymorphisms on toxicity and response in resectable osteosarcoma
65	Pirmohamed	CYP3A5 genetic polymorphisms and clopidogrel response in patients undergoing elective percutaneous coronary intervention (ePCI)
66	Woodahl	Cancer pharmacogenomics in American Indian populations
68	Zhang	Estimate locus-specific genetic effect on pharmacogenetic trait
69	Pirmohamed	Effects of <i>CYP4F2</i> genetic polymorphisms on clinical outcomes in patients initiated on warfarin therapy—A prospective study

Session 7 ADVANCES IN PHARMACOGENOMICS OF ADVERSE DRUG REACTIONS FRIDAY 11/21/2008, 7:30 PM

M. Pirmohamed / J.S. Leeder

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
70	Ross	Identification of novel genetic markers of severe hearing loss in children receiving cisplatin chemotherapy	25
71	Shen	Genome-wide association and candidate gene studies identify HLA-B*5701 as the major risk allele of drug-induced liver injury caused by flucloxacillin	25
72	Holden	The Serious Adverse Event Consortium, LTD, [SAEC]—Formation and current status of an international effort to understand the genetic basis of drug related serious adverse events	25
73	Brown	The development and optimization of a broad-based ADME genotyping assay	25
74	Rotger	Contribution of genetic variants identified through genome-wide analysis to dyslipidemia associated with antiretroviral therapy	25
75	Moyer	Acetaminophen-NAPQI pharmacogenomics—Genome-wide association study to identify biomarkers predicting toxicity	25

Session 8 MECHANISMS IN PHARMACOGENOMICS SATURDAY 11/22/2008, 9:00 AM

K. Giacomini / S. Liggett

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
76	Rubin	Genome wide set of human enhancers	25
77	Liggett	Genetic variation within GPCR signaling networks—From asthma to heart failure pharmacogenomics	25
78	Li	Thiopurine pharmacogenomics—Identification of candidate genes using a genome-wide model system approach	25
79	Mi	microRNA expression variation contributes to capecitabine susceptibility via regulation of mRNA	25
80	Kechris	Computational detection of regulatory polymorphisms for alcohol preference candidate genes	25
81	Zanger	Pathway-orientated functional genomics of CYP3A in human liver	25

R. Valdes / T. Moyer

<u>#</u>	<u>Iname</u>	<u>Title</u>	<u>Talk Length</u>
82	Valdes, Jr.	Practice guidelines in pharmacogenetics and the advent of clinical decision support tools—Convergence of PGX and informatics	25
83	Moyer	The power of public-private partnership in research—The Mayo-Medco warfarin pharmacogenomics project	25
84	Aitchison	Advances in pharmacogenomics from GENDEP, a multicentre European study	25
85	Chissoe	Development and application of genetics capabilities to differentiate medicines	25
86	Renaud	Development of a clinical genotyping panel to help guide tamoxifen treatment	25
87	Newman	The TARGET study—A randomized controlled trial of TPMT testing	25